HUMAN PLATELET LYSATE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Human Platelet Lysate Market is estimated to be valued at USD 60.6 Mn in 2026 and is expected to reach USD 83.9 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.

Increase in the mergers and acquisitions among key players to expand their product portfolio is expected to drive the growth of the global human platelet lysate market over the forecast period. Moreover, increase in the investment in research and development of human platelet lysate products is expected to drive the growth of the global human platelet lysate market over the forecast period. 

Analysts’ Views on Global Human Platelet Lysate Market:

The human platelet lysate market's growth is expected have a positive impact over the forecast period, owning to increasing in the government funding for stem cell research. For instance, in March 2020, the government of Canada invested around US$ 7 million in regenerative medicine and stem cell research.

Figure 1. Global Human Platelet Lysate Market Share (%), by Application, 2026

Global Human Platelet Lysate Market - Driver

Increasing in the research and development (R&D) activities of stem cell

Increasing in the research and development (R&D) activities of stem cell therapy by leading companies and governments are expected to drive market growth over the forecast period. For instance, in February 2022, the Government of India helped setting up state-of-the-art stem cell research facilities in 40 premier health research and educational institutions, in an effort to support the research and development in regenerative medicine in the country.

Increasing in the inorganic growth strategies such as partnership

Increasing in the inorganic growth strategies such as partnership by the key players is expected to drive the growth of the market over the forecast period. For instance, in March 11, 2022, Wipro, a global information technology, announced partnership with Pandorum Technologies, a biotechnology company, for development of regenerative medicine.

Figure 2. Global Human Platelet Lysate Market Share (%), by Region, 2026

Global Human Platelet Lysate Market - Regional Analysis

Among all regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the increasing prevalence of chronic diseases such as Parkinson’s disease, osteoarthritis, androgenetic alopecia and others. For instance, according to data published on July 25, 2026, on National Institutes of Health (NIH), stated that in the U.S. approximately 500,000 people are diagnosed with Parkinson’s disease every year.

The Europe region is expected to second largest region over the forecast period. Due to increasing adoption of advanced blood collection & processing technology are expected to drive market growth over the forecast period. For instance, on May 31, 2022, Vitestro, a medical device company announced the launch of autonomous device for blood collection. The new device combines artificial intelligence (AI) and ultrasound-guided 3D reconstruction with robotic needle insertion to ensure the precise and secure collection of blood.

Global Human Platelet Lysate Market Segmentation:

Global human platelet lysate market is segmented into type, application and end user.

Bases on Type, the market is segmented into heparin - based human platelet lysate and heparin - free human platelet lysate. Out of which, heparin - free human platelet lysate is expected to dominate the segment to dominate the global human platelet lysate market forecast period due to increase in adoption of heparin free human platelet lysate.

Based on Application, the market is segmented into clinical use and research use. Out of which, research use is expected to dominate the segment to dominate the global human platelet lysate market forecast period due to increase in the number of clinical trials. For instance, according to data published in January 2021, on Elsevier B.V., stated that in June 2020, there were approximately 1,138 registered   at clinicaltrials.gov for mesenchymal stem cells clinical trials.

Based on End User, the market is segmented into biopharmaceutical companies, contract research organizations and others. Out of which, biopharmaceutical companies is expected to dominate the segment to dominate the global human platelet lysate market forecast period due to increase in the inorganic growth strategies such as partnership by the key players. For instance, on May 17, 2022, AffyXell, a company focused is developing cell and gene therapies based on mesenchymal stem cell announced partnership with GenScript ProBio, part of Genscript Biotech Corporation, is a global contract development and manufacturing company (CDMO) which provides a platform for research and development of biological drugs, DNA plasmids and lentiviruses, and for clinical production of cell and gene therapy products. This partnership will give opportunity to accelerate the development of stem cell therapies.

Global Human Platelet Lysate Market Cross Sectional Analysis:

In application segment, research use held a dominant segment in North America region due to the increase in the number of funds for research use by the government. For instance, according to data published in September 2021, on Stanford Medicine, stated that three Stanford physician researchers have received a total of nearly US$ 31 million from the California Institute for Regenerative Medicine to launch first-in-human trials of stem cells to treat stroke, heart failure and a type of brain and spinal cord tumor.

In end user segment, biopharmaceutical companies held a dominant segment in Europe region due to the increase in the number of clinical trials in the region. For instance, according to data published in January 2021, on European Medicines Agency, stated that according to the European Clinical Trials Register, in Europe there were about 43,108 clinical trials in 2021.

Global Human Platelet Lysate Market: Key Developments

In June 2021, Captivate Bio, a scientific cell culture solutions provider, announced that it has signed an exclusive distribution agreement with PL BioScience GmbH, a biotech company to bring its portfolio of human platelet lysate to markets across North America. PL BioScience GmbH produces human-derived platelet lysate (HPL), a growth factor-rich supplement used for growing and expanding cells for applications such as cell therapy and tissue engineering.

In May 2020, CiRA Foundation, an institute focused on cell research and CGT Catapult, a biotechnological center launched a new collaborative research project aimed on induced pluripotent stem cell characterization.

In June 2020, Japan's Pharmaceutical and Medical Devices Agency (PMDA) had approved the start of Phase 2 clinical trial to evaluate the safety and efficacy of their mesenchymal stem cells that can be used to treat aging frailty.

In August 2022, StemCyte, Inc. obtained approval from U.S. FDA for their Phase II clinical trial for Post-COVID Syndrome using umbilical cord blood stem cell therapy.

Global Human Platelet Lysate Market: Restraint

High cost of human platelet lysate products

The major factors that hinder growth of the global human platelet lysate market include high cost of human platelet lysate products. Costs of human platelet lysate products are quite high as these need research and development process, and their manufacturing is a very complex process, which needs highly skilled scientists. For instance, according to data published in October 2021, on National Library of Medicine, stated that human platelet lysate (hPL) has higher production cost than foetal bovine serum, which is an alternative option of human platelet lysate (hPL).

Global Human Platelet Lysate Market: Key Players

Major players operating in the global human platelet lysate market  include STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck & Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific.

*Definition: Human platelet lysate is a growth factor-rich cell culture supplement derived from healthy donor human platelets. Fetal bovine serum (FBS) can be substituted with human platelet lysate (HPL) in both experimental and clinical cell culture. After a freeze-thaw cycle, it is a turbid, light-yellow liquid that is made from human blood platelets.